EGFR VACCINE TRIAL

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a study funded by the National Cancer Institute to study the safety and immunologic efficacy of the EGFRvIII peptide vaccine in patients whose tumors express the tumor specific antigen EGFRvIII and who are at high risk for relapse or progression of their cancer. This includes patients with ovarian, prostate and stomach cancers. The peptide vaccine will be administered with GM-CSF or KLH as adjuvant in order to: 1) evaluate the safety and define the potential toxicity of immunizing patients with an EGFRvIII based peptide vaccine; 2) determine the level of EGFR specific antibody response after immunization with EGFRvIII peptide; and 3) determine the level of EGFR specific T cell response after immunization with EGFRvIII peptide.